OBJECTIVE: To compare insulin-like growth factor-I (IGF-I) concentrations in obese and normal subjects, and evaluate the possible relationships between IGF-I concentrations and demographic, anthropometric, metabolic and hormonal variables in obese patients. SUBJECTS AND METHODS: 286 obese outpatients (OB, 234 female and 52 male; age 18 ± 71 y, body mass index (BMI) b 27 kgam 2 ) were recruited. MEASUREMENTS: BMI, waist-to-hip ratio (WHR), serum basal and oral glucose tolerance test (OGTT)-stimulated glucose and insulin concentrations, IGF-I, basal growth hormone (GH), prolactin (PRL), androgens, thyrotropin (TSH), free triiodothyronine (fT 3 ), free thyroxine (fT 4 ), free fatty acids (FFA), triglycerides, total and high density lipoprotein (HDL)-cholesterol, 24h-urinary cortisol levels and blood pressure (BP) values were measured. IGF-I concentrations were also evaluated in a large population of 326 age-matched controls (controls, 228 women, 98 men; age 20 ± 86 y, BMI`25 kgam 2 ). RESULTS: IGF-I concentrations were lower in OB than in controls (age-adjusted mean: 21.6 vs 23.6 nmolaL, P`0.03). However, individual IGF-I concentrations in OB were within the age-adjusted normal range. In both groups, IGF-I concentrations were gender-independent, and showed a simple negative correlation with age (r À0.47). In OB, univariate analysis also shows that IGF-I concentrations were negatively correlated with BMI (r À0.33), but not WHR, with both basal (r À0.16) and OGTT-stimulated glucose levels (r À0.17), as well as FFA levels (r À0.19), and with both diastolic and systolic BP (both r À0.17). In OB women, IGF-I concentrations positively correlated with PRL (r 0.31), testosterone (r 0.30), androstenedione (r 0.30), and dehydroepiandrosterone-sulfate (DHEAS) concentrations (r 0.41). No correlation was found with other variables. The multiple regression analysis showed that IGF-I concentrations were inversely and independently related to age and BMI only. CONCLUSIONS: In obesity, IGF-I concentrations are slightly reduced, but generally within the age-adjusted normal range. IGF-I concentrations in obesity show independent and negative relationships with age and BMI, but are not associated with fat distribution, insulin secretion, glucose tolerance, BP or risk indices for cardiovascular disease (CVD).
Introduction
Growth hormone (GH) stimulates insulin-like growth factor I (IGF-I) synthesis and release by the liver and other peripheral tissues;
1 IGF-I, in turn, regulates GH synthesis and release, and mediates many of its biological effects. 1 While GH secretion is pulsatile, IGF-I concentrations do not undergo signi®cant circadian variation and re¯ect the GH secretory status in physiological conditions. 2 However, IGF-I synthesis and release depends on nutrition, as well as on GH; 3 in fact, in malnourished and in anorexic patients, as well as in catabolic conditions, IGF-I concentrations are reduced in spite of exaggerated GH secretion. 3 In obesity, both spontaneous and stimulated GH secretion is clearly reduced; 4 nevertheless, it is still unclear if this means a true hypoactivity of the GHaIGF-I axis. In fact, total IGF-I concentrations in obese patients have been reported to be normal, 5 high 6 or reduced. 7 ± 10 Total IGF-I concentrations in obesity have been found to be negatively associated to body mass 7 ± 9 and restored by weight loss. 9 Obesity is associated with an increased risk of cardiovascular disease (CVD). 11 ± 13 Abnormalities in blood pressure (BP) values, basal and oral glucose tolerance test (OGTT)-stimulated glucose and insulin concentrations as well as in lipid concentrations, which are well-known risk factors for CVD, 11 ± 13 are generally present in obese patients. A large amount of data has pointed to a major role of the GHaIGF-I axis in the regulation of fuel metabolism. 1, 13, 14 In normal subjects, an inverse relationship between IGF-I and some CVD risk factors (such as BP, cholesterol and triglycerides) has been found 15 and, furthermore, lower IGF-I concentrations have been reported to be associated with increased CVD damage by some, 16 but not by other, 17 authors. Above all, in GH de®cient adults, abnormalities in body composition, glucose, lipids and protein metabolism, as well as an increase in CVD, have been clearly demonstrated and these abnormalities are corrected by replacement therapy with recombinant human (rhGH). 18, 19 Noteworthy, rhGH treatment has been recently reported to reduce visceral fat and metabolic abnormalities, even in patients with syndrome X. 13 Based on the foregoing, we aimed to clarify whether IGF-I concentrations are really reduced and if they have relationships with anthropometric, biochemical and hormonal variables, as well as BP in a large population of patients with simple obesity.
Thus, as serum samples from a large number of patients with simple obesity admitted to our clinical division from 1993 were available, we decided to measure IGF-I concentrations and to verify their relationships with the other available parameters.
Subjects and methods
In early 1997, we planned to perform a retrospective study on serum IGF-I concentrations in obese patients. To this goal, we revised the ®le of patients admitted to our Department for overweight problems from January 1993±December 1996. In this period, 525 obese patients had had clinical, biochemical and hormonal examinations and 312 of them had been classi®ed as having simple obesity, were free of any pharmacological treatment and had been on free diet for at least one month before the admission to our Department.
As serum samples (taken at the time of examination) from 286 of these patients were still available and suitable (frozen at À80 ) for IGF-I assay, IGF-I concentrations were measured. The relationships between these IGF-I concentrations and other available hormonal and metabolic parameters, were then evaluated.
Thus, the inclusion criteria for the obese subjects (OB) had been: a) patients with simple obesity (body mass index (BMI) b 27 kgam 2 ) admitted to our department from 1993±1997; b) availability of frozen serum samples for IGF-I assay.
The population in which IGF-I concentrations were measured included 234 female and 52 male subjects; BMI 36.2 AE 0.4 kgam 2 . The mean ( AE s.e.m.) age in OB was: 40.5 AE 0.8 y; the age distribution was as follows: 18±30 y: n 65; 31±40 y: n 66; 41±50 y: n 85; 51±60 y: n 47; b 61 y: n 23.
Anthropometric (height, weight, BMI, waist and hip circumferences that is, the minimum value between the iliac crest and the lateral costal margin, and the maximum value over the buttocks, respectively), basal metabolic (serum total and high density lipoprotein (HDL) cholesterol, triglycerides, free fatty acids (FFA), uric acid and glucose) and hormonal (serum GH, prolactin (PRL), free triiodothyronine (fT 3 ), free thyroxine (fT 4 ), thyrotropin (TSH), testosterone, androstenedione, dehydroepiandrosteronesulfate (DHEAS), sex hormone binding globulin (SHBG) and 24 h urinary cortisol) variables were also collected when available (Table 1) . Glucose and insulin values 120 min after a 75 g OGTT were also available in 249 and 155 patients, respectively. Basal systolic (SBP) and diastolic blood pressure (DBP) were also recorded in 276 out of 286 patients, and were the means of three measurements taken (with cuff size appropriate for obese patients) in the sitting position after a rest of at least 10 min. Of the 276 obese patients 139 were hypertensive, 103 out of 286 obese patients were smokers and 74 of them had hypertension.
Normative values for IGF-I concentrations were obtained from 326 normal lean (BMI`25 kgam 2 ) subjects (Controls, 228 female, 98 male), recruited from the personnel (and their relatives) of our Department. Their mean ( AE s.e.m.) age was: 49.3AE 1.0 y; the age distribution was as follows: 20±30 y: n 73; 31±40 y: n 41; 41±50 y: n 43; 51±60 y: n 54; b 61 y: n 115. In the controls no data other than age and gender were available.
All premenopausal obese (n 174) and lean women (n 115) were regularly cycling. In these subjects, IGF-I concentrations (and hormonal and metabolic values for obese subjects) were determined in the early follicular phase. Postmenopausal obese (n 57) and lean (n 113) women were not treated with estrogen replacement therapy.
Blood samples were taken in the morning after overnight fasting. Hormonal concentrations are a single assay of each hormone.
Serum IGF-I was measured by radioimmunoassay (RIA) provided by Nichols Institute Diagnostic (San Juan Capistrano, CA) after previous acid-ethanol extraction to avoid binding protein interferences. Inter-and intra-assay coef®cients of variation and sensitivity of the assay were 5.2±8.4%, 2.4±3.0% and 0.013 nmolaL, respectively.
The following hormones were measured by immunoradiometric assay: GH (HGH-CTK, Sorin, Saluggia, Italy), PRL (PRL-CTK, Sorin), cortisol (CORT-CTK125, Sorin), and TSH (hTSH, Biocode, Liege, Belgium). Inter-and intra-assay coef®cients of variation and sensitivity of the assay were 4.9± 6.5%, 1.5±2.9% and 0.1 mgaL, respectively, for GH; 3.9±6.8%, 3.3±7.5% and 0.45 mgaL, respectively, for PRL; 6.6±7.5%, 3.8±6.6% and 110.4AE 15.5 nmolaL, respectively, for cortisol; and 4.0±6.2%, 4.2±7.1% and 0.05 mUaL, respectively, for TSH.
The intra-assay coef®cients of variation were 6.5±15%, 4.5±13.4% and 17.9 AE 1.2 pmaL, respectively, for insulin; 6.5±9.8% and 3.5±5.8% and 5.0±15% and 3.7±6.5% for fT 3 and fT 4 , respectively; 6.8±10.0% and 6.5±9.4%, respectively, for respectively testosterone; 5.7±9.8% and 4.8±6.6%, respectively, for androstenedione; 5.3±9.4% and 5.5±7.8%, respectively, for DHEA-S; and 6.5±8.3% and 4.1%, respectively, for SHBG. The sensitivity of the assays were: 28.7 pmolaL for insulin, 0.5 pmolaL for fT 3 and 0.6 pmolaL for fT 4 , 0.2 mmolaL for testosterone, 1.0 nmolaL for androstenedione, 0.03 mmolaL for DHEA-S and 5 mgaL for SHBG.
Total and HDL-cholesterol, triglycerides and uric acid were measured by enzymatic colorimetric tests using commercial kits provided by Boehringer Mannheim, Germany (CHOL, TG and UA PLUS, respectively; HDL-cholesterol after separation with Magnetic HDL Cholesterol Reagent provided by Reference Diagnostics, Inc., Aterington, USA); FFA by enzymatic analysis using the non esteri®ed fatty acids (NEFA) QUICK BMY kit (Boehringer Mannheim Yamanouchi K.K., Tokyo, Japan); glucose by glucose oxidase colorimetric method (GLUCOFIX, Menarini Diagnostici, Florence, Italy). SBP and DBP were determined with an automatic non invasive portable recorder (SpaceLabs, Inc, Redmond, WA, USA).
The study was approved by the Ethical Commitee of our Department.
Statistical analysis
The following statistical tests were used: Pearson's product moment correlation, multiple linear regression. Analysis of covariance (age as covariate) and Newman-Keuls test was used to compare IGF-I values between OB and controls and BMI means by quartiles of IGF-I concentrations. To improve skewness, log transformation of IGF-I concentrations was performed before statistical analysis. Unless otherwise stated, all results are expressed as the mean with the standard error of the mean (s.e.m.)
Results IGF-I concentrations were gender-independent either in OB (female vs male: 22.5 vs 23.1 nmolaL, ageadjusted means) or in controls (22.7 vs 22.2 nmolaL) and showed a progressive decrease with age in both groups Figure 1 . In the whole groups, age-adjusted mean IGF-I concentrations in OB were lower than in the controls (21.6 vs 23.6 nmolaL, P`0.03) while, dividing subjects for decade of life, the difference attained statistical signi®cance in the fourth decade (Figure 1 ). However, individual IGF-I concentrations in OB were generally within the agerelated normal range (Figure 1 ) IGF-I concentrations in hypertensive and normotensive, as well as in smoker and non smoker, obese patients were similar. Within the whole OB group, IGF-I concentrations showed a strong negative correlation with age (r À0.47, P`0.0001), BMI (r À0.33, P0
.0001) and weakly with height (r 0.15, P`0.02), but not with the waist-to-hip ratio (WHR) ( Table 2) .
IGF-I concentrations were also negatively associated to basal and OGTT-stimulated plasma glucose levels (r À0.16, P`0.01 and r À0.17, P`0.01, respectively), FFA levels (r À0.19, P`0.02) and both SBP and DBP (both r À0.17, P`0.01) ( Table 2) .
No relationship was found between IGF-I and GH, thyroid hormones, TSH, basal and OGTT-stimulated insulin concentrations as well as with urinary cortisol, lipids and uric acid ( Table 2 ). In female, but not in male, OB, IGF-I concentrations were found to be positively related to PRL (r 0.31, P`0.0001), testosterone (r 0.30, P`0.0001), androstenedione (r 0.30, P`0.0001) and DHEAS (r 0.41, P`0.0001), but not to SHBG levels ( Table 2) .
Dividing OB by quartiles of IGF-I levels and assuming age as covariate, only BMI demonstrated a signi®cant (P`0.0001) progressive reduction with IGF-I increase (1st vs 4th IGF-I quartile: 40.4 vs 33.6 kgam 2 ); none of the other variables showed signi®cant variations.
The evaluation of the data in the whole OB group by multiple linear regression analysis ( Table 3 ), showed that IGF-I concentrations were still (P`0.0001) negatively and independently, associated with age and BMI. By this analysis, no other signi®cant correlation was found.
In female OB (Table 4) , multiple regression analysis showed that IGF-I concentrations were positively associated with PRL (P`0.04) and DHEA-S (P`0.01), independent of age and body mass.
Discussion
The results of the present study for a large population of obese patients demonstrate that total IGF-I concentrations are slightly reduced, but generally within the age-adjusted normal range. In fact, in obese as well as in normal subjects, total IGF-I concentrations undergo a clear age-related reduction. 8, 15 In obesity, IGF-I concentrations are negatively and independently associated with age and BMI; our present ®ndings indicate that all simple linear relationships between IGF-I concentrations and other variables are a function of age and body mass, with the notable exception of the *P`0.05, **P`0.01, ***P`0.0001 HDL high density lipoprotein; T 3 ; T 4 ; DHEAS dehydroepiandrosterone-sulfate; SHBG sex hormone binding globulin.
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positive and independent correlation of IGF-I concentrations with PRL and DHEA-S concentrations in obese women. It is widely accepted that IGF-I synthesis and release depends on GH secretion 1 and that IGF-I concentrations re¯ect the GH secretory status.
2 However, other hormones (such as insulin and glucocorticoids), as well as metabolic fuels (particularly amino acids and glucose 3 ), have an important in¯uence on IGF-I synthesis and release. In fact, in spite of exaggerated GH secretion, IGF-I concentrations are markedly reduced in malnutrition and anorexia nervosa, as well as in catabolic states. 3 Previous data about total IGF-I concentrations in obesity, are contradictory. 5±10 Our present ®ndings for a large population of obese patients con®rm that total IGF-I concentrations are inversely related with BMI and slightly lower than those in normal lean controls. However, it has to be emphasized that IGF-I concentrations in obese patients are generally within the age-adjusted normal range.
In agreement with some authors, 20, 21 we found an age-related, but not gender-related, difference in IGF-I concentrations, both in normal and obese subjects. However, IGF-I concentrations have been reported to be higher in women than in men by some authors; 8, 15 as only a small number of obese men were included in our study, we cannot de®nitively rule out the possible existence of some gender-related difference in IGF-I concentrations.
The most likely explanation for the slight reduction of IGF-I concentrations in obesity is the marked impairment of both spontaneous and stimulated GH secretion, which has been clearly shown to be negatively and independently associated to age and BMI; 4 in agreement with this evidence we found a negative and independent correlation of IGF-I concentrations with age and BMI. Indeed, we did not ®nd any association between IGF-I concentrations and WHR, but we did not accurately measure visceral fat by computed tomography (CT). 10 Exaggerated FFA levels in obesity seem to play a major role in inhibiting somatotropin secretion, 22 and may also negatively in¯uence hepatic IGF-I secretion, as shown in rats. 23 Attention has to be given, however, to evidence showing that total IGF-I concentrations do not necessarily re¯ect IGF-I activity. 1 In fact, an increase in free IGF-I concentrations has been recently reported in young obese patients; 24 this ®nding could be explained by the reduction in IGFBP-1 concentrations which, in turn, could be caused by hyperinsulinaemia. 25 In fact, it is still a matter of debate why, in obesity IGF-I concentrations do not re¯ect the GH secretory status (that is, IGF-I concentrations are only slightly reduced despite marked impairment of somatotropin secretion). 4 GH-binding protein (GHBP) levels, which probably re¯ect the GH receptor status, are increased in obesity, 6 suggesting that peripheral GH sensitivity is increased. Overfeeding per se could stimulate IGF-I production, although short term overfeeding failed to normalize IGF-I in GH de®cient patients.
3 
On the other hand, it has to be emphasized that insulin possesses an inhibitory in¯uence on GH secretion, 26 but is able to enhance the GH-induced increase in IGF-I synthesis and release. 27 Thus, hyperinsulinaemia could account for the near normal IGF-I concentrations, in spite of marked GH hyposecretion in obesity. However, in our study and other studies, 5, 9 no association was found between IGF-I and both basal and OGTT-stimulated insulin concentrations in obese patients.
Glucocorticoids stimulate IGF-I concentrations, 28 which are normal in spite of marked GH insuf®ciency in Cushing's syndrome 29 .
As hypothalamo-pituitaryadrenal hyperactivity has been reported in obesity, 30 this could account for near normal IGF-I concentrations. However, we found no relationship between IGF-I concentrations and 24 h urinary cortisol values.
Interestingly, we found a positive and independent association of IGF-I concentrations with PRL and DHEAS concentrations. This was only found in obese women but as only a small number of obese men were included in our study this does not allow us to de®ne a gender-related difference.
Indeed, PRL binds to GH receptors and probably stimulates IGF-I secretion; 31 in fact, IGF-I concentrations have been reported to be high±normal in hyperprolactinaemic patients. 32 On the other hand, prolonged treatment with high DHEA doses has been found to be able to increase IGF-I concentrations in man by some, 33 but not by other authors. 34 At present, there is no clear evidence supporting the hypothesis that PRL and DHEAS secretion plays a role in maintaining near normal IGF-I concentrations in obesity. On the contrary, IGF-I could modulate adrenal DHEAS synthesis and secretion. 35 In patients with ischaemic heart disease, a negative association between IGF-I and coronary damage 16 has been reported. Furthermore, premature atherosclerosis and higher mortality for CVD have been clearly demonstrated in hypopituitary patients with GH de®-ciency. 18 In fact, they generally show metabolic alterations such as insulin resistance, hypertriglyceridaemia and low HDL-cholesterol, 36 which are also common in most of patients with visceral adiposity. 11, 12 Notice that rhGH therapy restores biochemical and metabolic alterations in GHD, 19 even in visceral obesity, 13 pointing to an important role for reduced activity of GHaIGF-I axis in the outcome of CVD.
Our present data do not support the hypothesis that the increased risk of CVD which occurs in obesity is related to metabolic alterations due to IGF-I hypoactivity. In fact, IGF-I concentrations in our obese patients were not associated with total and HDL cholesterol, triglyceride and uric acid concentrations, as well as with basal and OGTT-stimulated insulin concentrations. Moreover, the negative association between IGF-I concentrations and basal and OGTTstimulated glucose concentrations or basal FFA concentrations or PAS and PAD disappeared when the data where analysed by multivariate analysis, suggesting that these relationships were a function of age and BMI.
Conclusion
In obesity, IGF-I concentrations are slightly reduced, but generally within age-adjusted normal range. IGF-I concentrations in obesity show independent and negative relationships with age and BMI, but are not associated with fat distribution, insulin secretion, glucose tolerance, BP and risk indices for CVD.
